Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload

Author： Cappellini MD   Taher A  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.9, Iss.13, 2008-09, pp. : 2391-2402

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload

By  

Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

ICL 670: effective oral iron chelation therapy

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Deferasirox: A Review of its Use in the Management of Transfusional Chronic Iron Overload

By Yang Lily P.H.   Keam Susan J.   Keating Gillian M.  

Drugs, Vol. 67, Iss. 15, 2007-01 ,pp. : 2211-2230

Adis International

Access to resources Recommend Favorite

Deferasirox: a guide to its use in transfusional chronic iron overload

By Adis International Limited  

Drugs & Therapy Perspectives, Vol. 24, Iss. 2, 2008-02 ,pp. : 1-4

Adis International

Access to resources Recommend Favorite

Long-Term Chelation Therapy with Deferasirox: Effects on Cardiac Iron Overload Measured by T2* MRI

By >   Borsellino Zelia   Cuccia Liana   >   Gagliardotto Francesco   Tarantino Rossana  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 267-273

Adis International

Access to resources Recommend Favorite